The observed effects in animal models suggest that MC4R agonists could be valuable as neuroprotective and neurodegenerative agents in various neurodegenerative diseases, addressing a significant unmet medical need, such as in multiple sclerosis (MS). Here, MC4R is linked to multiple sclerosis.